Dr. Mattison chairs NAM report

Compounded medications prepared by pharmacists or physicians have been used extensively throughout history as a mainstay of therapeutics.  Over the past half-century – with the increasing focus on evidence based treatment the use of compounded medications substantially decreased.  However, in some therapeutic areas, such as menopause, use of compounded medications continues. 

Risk Sciences International 1

The continuation of use of compounded medications represents a challenge to the USFDA because the standard evaluations of benefit and risk are not required. 

To gain guidance in this concern the FDA asked the National Academies of Sciences, Engineering and Medicine to form a consensus committee to characterize the clinical utility of compounded bioidentical hormone therapy. 

The committee was chaired by  Dr. Donald Mattison the Chief Medical Officer of Risk Sciences International and composed of a dozen clinicians and scientists who worked together over the course of 1.5 years to pull the literature on risk-benefit, and clinical utility of compounded bioidentical hormone therapy.  The publication can be downloaded here.

The committee concluded (Conclusion 9.1) that there is insufficient evidence to support the overall clinical utility of compounded bioidentical hormone therapy as treatment for menopause and male hypogonadism symptoms. 

Posted in

More RSI News

Dr. Mattison chairs NAM report

July 24, 2020
National Academy of Sciences review chaired by Dr. Mattison

Compounded medications prepared by pharmacists or physicians have been used extensively throughout history as a mainstay of therapeutics.  Over the past half-century – with the…

Read News Item

COVID-19 timeline by RSI

May 23, 2020
Screen grab of RSI's Covid-19 timeline

As part of its new Risk & Crisis Communication Master Class & Boot Camp, and its ongoing commitment to keep its understanding of major public…

Read News Item

Country Foods Forum

March 1, 2020
Cover of Health Canada, RSI-organized, Country Foods Forum highlights

Leading up to February 11 and 12, 2020, Risk Sciences International had the privilege of assisting Health Canada in its organization of the Country Foods…

Read News Item

Workshop on Evidence Integration December 5-6, 2019

November 11, 2019
RSI logo in white

Risk Sciences International is organizing a two day Workshop on Evidence Integration in support of human health risk assessment in collaboration with the McLaughlin Centre…

Read News Item